<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317393</url>
  </required_header>
  <id_info>
    <org_study_id>TERMATEP</org_study_id>
    <nct_id>NCT02317393</nct_id>
  </id_info>
  <brief_title>Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy</brief_title>
  <acronym>TERMATEP</acronym>
  <official_title>A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the contribution of the imaging to the expression of
      intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the
      end of chemotherapy.

      The investigators hope that the results of this first stage of the clinical trial come to
      consolidate the preclinical results obtained by the investigators team to characterizing the
      interest and the strong contribution of the use of a tracer resting on the expression of αvβ3
      integrine for the diagnosis of simple necrosed mass at the end of the treatment of a
      non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of teratoma</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Efficacity to differentiate mature teratoma and necroses within the residual masses of germinal non-seminoma tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>Number of patients having at least a tumor detected by TEP K5-RGD requiring a surgery, divided by the number of patients having actually at least a tumor (by anatomopathologie) requiring a chirurgie</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Non-seminomatous Germ Cell Tumors</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>K5-RGD PET + FDG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>K5-RGD PET</intervention_name>
    <description>Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy</description>
    <arm_group_label>K5-RGD PET + FDG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FDG</intervention_name>
    <description>Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy</description>
    <arm_group_label>K5-RGD PET + FDG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged 18 years or more

          -  Patients with one or several ganglionic or visceral residual masses (&gt; to 1 cm) after
             chemotherapy for metastatic non-seminoma testicular tumor, and for which or which a
             surgery is planned;

          -  Affiliate to a social security system;

          -  Signed written Informed consent

        Exclusion Criteria:

          -  Patient deprived of liberty as a result of a justice or administrative decision

          -  Any medical or psychological condition which could compromise the capacity of the
             patient to participate in the study;

          -  Previous or concomitant other cancer in 5 years except basal cell carcinomas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas AIDE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse, CAEN, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnaud DOERFLER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Côte de Nacre, CAEN, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre VERA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel, ROUEN, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas AIDE, Pr</last_name>
    <email>&quot;Dr Nicolas AIDE&quot; &lt;naide@baclesse.unicancer.fr&gt;;</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD, CRA</last_name>
    <email>jm.grellard@baclesse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas AIDE, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas AIDE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud DOERFLER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY, Pr</last_name>
      <email>f.joly@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Florence JOLY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura MOISE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre VERA, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Pierre VERA, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PFISTER Christian, Pr</last_name>
    </contact>
    <investigator>
      <last_name>PFISTER Christian, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine CHEVREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loic MOURREY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa COTTURA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos GOMEZ-ROCA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah ZAHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slimane ZERDOUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2014</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nuclear medicine</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>avb3 integrin expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

